Drug intelligence / Profile preview

(R)-Mexiletine

Development stage: Approved
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Mexiletine is a small molecule antiarrhythmic drug belonging to the class of phenol ethers. It is a chiral compound and the (R)-enantiomer of mexiletine. Mexiletine acts primarily as a sodium channel blocker in cardiac tissue and is used for its membrane-stabilizing properties to treat ventricular arrhythmias. The compound inhibits sodium influx during depolarization of cardiac cells, thereby reducing abnormal electrical activity in the heart. Mexiletine has also been investigated for other indications such as neuropathic pain but its primary use remains in cardiology[1][2][4].

Other names: 94991-73-82-Propanamine 1-(2,6-dimethylphenoxy)-(2R)(R)-(-)-Mexiletine

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on (R)-Mexiletine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on (R)-Mexiletine.

Explore the full profile